CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionCurrent ratio is 38×, higher than 95% of its Biotechnology peers (median 5.64×)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
532.01MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.7030xvs all stocks
52-Week Change
151.86%vs all stocks
Market Capitalization
532.01MUSDvs all stocks (USD)
Enterprise Value
292.63MUSDvs all stocks (USD)
Forward P/E
-7.84xvs Biotechnology peers
Price to Book (MRQ)
2.13xvs Biotechnology peers
Enterprise to EBITDA
-4.40xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-18.18%vs Biotechnology peers
Return on Equity (TTM)
-26.88%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 18, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-66.53MUSDvs all stocks (USD)
Net Income (TTM)
-58.44MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-57.17MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-39.01MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-68.06MUSDvs all stocks (USD)
Pre-tax Income
-59.98MUSDFY2025 · Dec 31, 2025Net Income
-59.98MUSDFY2025 · Dec 31, 2025EBIT
-68.06MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-67.74MUSDFY2025 · Dec 31, 2025Research & Development
51.52MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
16.54MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
8.25MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-59.98MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-50.66MUSDFY2025 · Dec 31, 2025Free Cash Flow
-50.90MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
75.60MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-59.98MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
323.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
10.04MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.08MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-869.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.26MUSDFY2025 · Dec 31, 2025Capital Expenditures
-231.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-162.50MUSDFY2025 · Dec 31, 2025Sale of Investments
159.02MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-3.71MUSDFY2025 · Dec 31, 2025Other Financing Charges
-256.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
112.00MUSDFY2025 · Dec 31, 2025Shares Outstanding
37.39MSharesUpdated Jul 18, 2026Float Shares
27.59MSharesUpdated Jul 18, 2026Shares Short
2.14MSharesUpdated Jul 18, 2026Short Ratio
4.61daysvs all stocks
Short % of Shares Outstanding
6.57%vs all stocks
% Held by Insiders
0.53%vs all stocks
% Held by Institutions
94.12%vs all stocks
Total Cash (MRQ)
246.33MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
6.59USDUpdated Jul 18, 2026Total Debt (MRQ)
6.95MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0278xvs Biotechnology peers
Current Ratio (MRQ)
38.00xvs Biotechnology peers
Book Value per Share (MRQ)
6.69USDUpdated Jul 18, 2026Total Assets
276.64MUSDvs all stocks (USD)
Total Current Assets
267.92MUSDFY2025 · Dec 31, 2025Total Liabilities
15.65MUSDFY2025 · Dec 31, 2025Total Non-current Assets
8.72MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
5.91MUSDFY2025 · Dec 31, 2025Total Current Liabilities
9.74MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
75.60MUSDFY2025 · Dec 31, 2025Other Short-term Investments
187.29MUSDFY2025 · Dec 31, 2025Accounts Payable
1.02MUSDFY2025 · Dec 31, 2025Short-term Debt
2.34MUSDFY2025 · Dec 31, 2025Long-term Debt
5.91MUSDFY2025 · Dec 31, 2025Common Stock (Book)
37.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-177.38MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
260.99MUSDvs all stocks (USD)
52-Week Low
4.67USDUpdated Jul 18, 202652-Week High
16.91USDUpdated Jul 18, 202652-Week Change
151.86%vs all stocks
Beta
0.7030xvs all stocks
50-Day MA
13.56USDUpdated Jul 18, 2026200-Day MA
12.75USDUpdated Jul 18, 2026Avg 10-Day Volume
308.76KSharesUpdated Jul 18, 2026Avg 30-Day Volume
423.53KSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-1.94USDUpdated Jul 18, 2026Other Income / Expense
-165.00KUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 38×, higher than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 38.00Industry median: 5.64Industry P95: 23.02Peers compared: 261
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.58
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Assembly Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai General Healthy Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Miracure Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Verastem Inc.
Tier 1ProductionApproval-Gated PipelineRule
Eikon Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Jiangsu Bioperfectus Technologies Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Wuhan Easydiagnosis Biomedicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hinova Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Bliss GVS Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Lifestrong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Olaplex Holdings, Inc.
1 interpretationLow-Leverage Liquidity Configuration
Data Patterns (India) Limited
1 interpretationLow-Leverage Liquidity Configuration
Enliven Therapeutics, Inc.
1 interpretationLow-Leverage Liquidity Configuration